ArticleCureus2026
Sclerosing Encapsulating Peritonitis Is More Common Following Repeat Hyperthermic Intraperitoneal Chemotherapy.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSclerosing encapsulating peritonitis (SEP) is a rare complication of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC). The purpose of this study is to determine the incidence and risk factors for developing SEP, as well as to characterize the clinical presentation, diagnosis, and management outcomes of SEP.
methodsThis study was conducted at the University of Colorado Anschutz in Aurora, Colorado, a tertiary referral center for peritoneal surface malignancies. Patients undergoing CRS with or without HIPEC were identified from our retrospective CRS/HIPEC database. Patients with clinical, operative, and/or radiologic features of SEP were identified, and their clinical parameters were compared with those of patients without these findings.
resultsBetween January 1, 2017, and June 1, 2025, 500 patients underwent CRS with (n = 388) or without HIPEC (n = 112). Six patients developed the typical clinical and radiologic findings of SEP, including chronic or recurring small bowel obstruction, postprandial abdominal pain, vomiting, weight loss, and persistent small bowel dilation on CT scans. The median time from the most recent CRS/HIPEC to presentation with SEP was 5.5 months (range 2-11). Five of six patients underwent laparotomy, with four receiving surgical resection of the encapsulating fibrous rind. Symptoms resolved in four patients with no recurrence. One patient developed a chronic enterocutaneous fistula and is total parenteral nutrition (TPN) dependent. One patient opted for observation and has ongoing symptoms of SEP. SEP was significantly more common (p < 0.05) in patients following repeat (>2) HIPEC (3/53, 5.7%) than an initial HIPEC (3/335, 0.9%).
conclusionsSEP is a rare complication of HIPEC that presents within a year of HIPEC with chronic or recurrent bowel obstruction secondary to adhesions encasing the small bowel. The risk of SEP increases with repeat CRS/HIPEC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.